March 24, 2022 7:34am

The cell and gene therapy sector last Friday advanced, Monday declined, Tuesday advanced, Wednesday declined and today, Thursday … back to the upside?

Pre-open indications: 1 SELL, 11 BUYs and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.48% (+165 points), S&P futures are UP +0.64% (+28 points) and NASDAQ futures are UP +0.73% (+107 points)

 

Stock futures rose in Thursday pre-open market as investors hoped to recover from declines in Wednesday’s session,

European stocks were slightly higher,

Asia-Pacific markets struggled for direction as yesterday’s 5% jump in oil prices took a pause.

 

Henry’omics:

Wednesday marked two years since the S&P 500 bottomed in the 2020 global stock market crash after the World Health Organization moved to declare COVID-19 an official pandemic.

Economic Data Docket: weekly jobs claim data and durable goods orders

 

RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: after yesterday’s gains, there’s today’s pains – yet again” … https://www.regmedinvestors.com/articles/12356

Ebb and flow –

·         March – 9 negative and 8 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  (FIXX) added, 30 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

SELL:

  • Global Blood Therapeutics (GBT -$0.11) -0.51 or -1.52% pre-open indication

BUY:

  • Beam Therapeutics (BEAM -$4.90) +$1.19 or +2.10% pre-open indication
  • Precigen (PGEN -$0.08) +$0.10 or +4.74% pre-open indication
  • AxoGen (AXGN -$0.60) +$0.07 or +0.89% pre-open indication
  • BioLife Solutions (BLFS -$1.00) +$0.44 or +1.98% pre-open indication
  • Cellectis SA (CLLS +$0.09) +$0.26 or +5.99% pre-open indication
  • CRISPR Therapeutics (CRSP -$3.93) +$1.66 or +2.61% pre-open indication
  • MiMedx (MDXG -$0.22) +$0.23 or +4.94% pre-open indication
  • Intellia Therapeutics (NTLA +$0.06) +$0.76 or +1.08% pre-open indication
  • Sage Therapeutics (SAGE -$1.15) +$0.40 or +1.19% pre-open indication
  • Sangamo Therapeutics (SGMO -$0.34) +$0.11 or +1.91% pre-open indication
  • Vericel (VCEL +$0.77) +$0.90 or +2.58% pre-open indication

Pimp/Pump and Promote:

  • Biostage (OTCQB: BSTG) closed flat Wednesday with 4 shares traded after Tuesday’s down -$0.17 with 202 shares traded after Monday’s flat with 5 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

 

The BOTTOM LINE: The sector fell after flipflopping for session after session as the stock market rally suffered its biggest loss since March 14.

While down days aren't fun, a brief market rally pause could be beneficial.

That would let stocks such as Beam Therapeutics (BEAM -$4.90) with a pre-market of +1.19 or +2.10% and Precigen (PGEN -$0.08) with a premarket of +$0.10 or +4.74% to take a fall.

It’s time to be flexible, don't get locked into a specific “names” watch CLOSELY directional movements   with an open mind to exit or buy-in.

I’m never totally wrong but, not always wholly right after Tuesday, Wednesday and now - Thursday.

With the recent lows and highs, the wash-out equities highs and resulting lows remain at the mercy of the latest headline as war and killing news, Fed questions and the lack of positive sector news is the bane of March lifting or sinking the major indexes.

I STILL say, cut or partially sell into strength without totally removing holdings.

There are still plenty of hurdles i.e., as economy faces struggles, European war headlines - hopes of progress in talks between the two sides last week fading, and maybe further earnings surprises - another eight (8) are due.

There is no clear trend ….

Earnings’ reporting on the horizon:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.